Novo Nordisk’s Indian team is urging the Danish pharmaceutical company to expedite the launch of its weight-loss drug Wegovy to counter Eli Lilly’s upcoming rival product, Mounjaro. Sources close to the discussions revealed that while Novo originally planned a 2026 India launch, internal teams are advocating for a 2024 rollout.
Key Developments
- Launch Timeline: Initially slated for a 2026 release, Novo’s India team is lobbying for a 2024 launch of Wegovy, aligning with Eli Lilly’s expected introduction of Mounjaro.
- India’s Market Dynamics: India has seen a sharp rise in obesity rates, with government data showing 24% of women and 23% of men classified as overweight or obese.
- Rising Demand: Obesity treatment awareness campaigns by Novo have spurred interest, with many patients inquiring about weight-loss medications.
Industry Challenges
- Global Supply Issues: Novo Nordisk and Eli Lilly are grappling with high demand for their GLP-1 receptor agonist drugs, limiting immediate global availability.
- Regulatory Status: Novo received approval for semaglutide, Wegovy’s active ingredient, in India in late 2022 but awaits further production scale-ups.
- Competition: India’s generic drugmakers, including Cipla and Dr. Reddy’s, are preparing lower-cost versions, while Sun Pharma is developing its own GLP-1-based experimental drug.
Broader Context
Novo launched Wegovy in China last month at a competitive price of 1,400 yuan ($193.27) per starter dose, significantly lower than the U.S. list price of over $1,300. This pricing strategy may influence its approach in India, where affordability is crucial.